Indeed, an important issue for the potential cognitive and mental health effects of GLP-1RAs, which our analysis cannot fully address, is whether these medications provide symptomatic relief only via their well-established cardiometabolic benefits, or by directly targeting physiopathological mechanisms behind cognitive and mental symptoms
In March 2026, Structure reported 44-week topline data from the ACCESS II Phase 2 study, showing placebo-adjusted weight loss of up to 16.3%, which the company described as the highest efficacy demonstrated among oral GLP-1 receptor agonists at that time point
Clinical trials show that this drug may help a lot with weight loss and glycemic control
To help, we tapped three doctors who prescribe these medications to break it all down
We update this list as new data comes in
Pharma giant Eli Lilly also is pushing to get FDA approval for tirzepatide, a diabetes medication, to be added to the weight loss market in the U.S